ATX Amplia Therapeutics Ltd
- 0.057
- -0.010-14.93%
Amplia Therapeutics Ltd News
Amplia Therapeutics Ltd: Preliminary Final Report and Annual Report YE 31 March 2024
Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing
Amplia Therapeutics (ASX:ATX) is seeking to raise AU$4.3 million via a nonrenounceable entitlement offer of 77.6 million shares at AU$0.055 per share, according to a Tuesday filing with the Australian
Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II
Amplia Therapeutics (ASX:ATX) provided an update on the clinical trials of its AMP945 anti-pancreatic cancer medication, saying response rates from the first stage of the study "continue to be substan
Amplia Therapeutics Updates on Pancreatic Cancer Trial; Phase-Two Recruitment Ongoing; Shares Up 3%
Amplia Therapeutics (ASX:ATX) reported "substantially better" response rates from the first phase of its pancreatic cancer drug trial amidst ongoing patient recruitment for the second phase, a filing
Amplia Therapeutics Secures US FDA Clearance for Proposed Pancreatic Cancer Trial
Amplia Therapeutics (ASX:ATX) secured an investigational new drug application clearance from the US Food and Drug Administration for its proposed US clinical trial in patients with pancreatic cancer.
Amplia Therapeutics Doses First Patient in Phase 2A Pancreatic Cancer Trial
Amplia Therapeutics (ASX:ATX) dosed the first patient for its phase 2a trial, investigating the efficacy of its inhibitor drug narmafotinib combined with chemotherapy to treat advanced pancreatic canc
Amplia Therapeutics Secures South Korean Regulatory Approval for Pancreatic Cancer Trial; Shares Up 3%
Amplia Therapeutics (ASX:ATX) secured approval from the Korean Ministry of Food and Drug Safety to start phase two of the ACCENT pancreatic cancer trial in South Korea. The clinical trial will test na
Amplia Therapeutics Receives AU$2.4 Million R&D Tax Rebate
Amplia Therapeutics (ASX:ATX) received a refund for research and development tax of AU$2.4 million for 2022/2023. The refund is related to spending associated with the company's antitumor agents, AMP9
Amplia Therapeutics Appoints CFO
Amplia Therapeutics (ASX:ATX) appointed Tim Luscombe as chief financial officer, succeeding Hamish George. Luscombe is a director at Bio101 Financial Advisory and has been working with the pharmaceuti
Amplia Therapeutics (ASX:ATX) Receives Grant Funding to Support Research Collaboration With CSIRO
Amplia Therapeatuics (ASX:ATX) Recruits First Patient in Cohort Three of Trial for Pancreatic Cancer
Analysis
Price Target
No Data
